<DOC>
	<DOCNO>NCT02172287</DOCNO>
	<brief_summary>To compare long -term ( six month ) bronchodilator efficacy safety tiotropium inhalation capsule , salmeterol inhalation aerosol placebo patient COPD . A secondary objective study compare impact tiotropium salmeterol humanistic economic health outcome , quality life , patient preference Health Resource Utilisation patient population .</brief_summary>
	<brief_title>Multiple Dose Comparison Tiotropium Inhalation Capsules , Salmeterol Inhalation Aerosol Placebo Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>1 . Age ≥ 40 year . 2 . A diagnosis relatively stable , moderate severe COPD : 3 . Screening FEV1 ≤ 60 % predict normal value ( calculate accord European Community Coal Steel ( ECCS criterion R94 R1408 ) screen FEV1 ⁄ FVC ≤ 70 % ) . 4 . Smoking history ≥ 10 packyears ( packyear 20 cigarette per day one year equivalent ) . 5 . Ability train proper use HandiHaler® device Mahler Dyspnoea Index ( MDI ) . 6 . Ability perform study related test include Shuttle Walking Test , acceptable pulmonary function test , include Peak Expiratory Flow Rate ( PEFR ) measurement , maintenance daily diary card record . 7 . Ability give write informed consent accordance Good Clinical Practice ( GCP ) local regulation . 1 . Clinically significant disease COPD . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinically relevant abnormal baseline haematology , blood chemistry urinalysis , abnormality defines disease list exclusion criterion , exclude . 3 . All patient serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamic pyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . Repeat laboratory evaluation conduct patient . 4 . A recent history ( i.e. , one year less ) myocardial infarction . 5 . Any cardiac arrhythmia require drug therapy hospitalisation heart failure within past three year . 6 . Inability abstain regular daytime use oxygen therapy 1 hour per day . 7 . Known active tuberculosis . 8 . History cancer within last five year ( exclude basal cell carcinoma ) . 9 . History lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 10 . Patients undergone thoracotomy pulmonary resection . 11 . Any upper respiratory infection past six week prior screen visit runin period . 12 . Current participation pulmonary rehabilitation programme completion pulmonary rehabilitation programme six week prior screen visit . 13 . Known hypersensitivity anticholinergic drug , salmeterol , component lactose powder capsule MDI delivery system . 14 . Known symptomatic prostatic hypertrophy bladder neck obstruction . 15 . Patients know narrowangle glaucoma . 16 . Current treatment cromolyn sodium nedocromil sodium . 17 . Current treatment antihistamine ( H1 receptor antagonist ) . 18 . Oral corticosteroid medication unstable dos ( i.e . le six week stable dose ) dose excess equivalent 10 mg prednisolone per day 20 mg every day . 19 . Current use βblocker medication . 20 . Current treatment monoamine oxidase inhibitor tricyclic antidepressant . 21 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception . 22 . Patients history asthma , allergic rhinitis atopy total blood eosinophil count ≥ 600 mm3 . A repeat eosinophil count permit . 23 . History and/or active significant alcohol drug abuse . 24 . Concomitant recent use investigational drug within one month six half life ( whichever great ) prior screen visit . 25 . Changes pulmonary therapeutic plan within six week prior screen visit . 26 . Inability comply medication restriction specify Section 4.2 trial protocol .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>